Clinical trial
Study Assessing 20 mg/kg Dose of the Recombinant Human Monoclonal Antibody Against P-selectin in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery
NCT01245634 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Study Assessing 20 mg/kg Dose of the Recombinant Human Monoclonal Antibody Against P-selectin in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2010
- Completion date
- May 31, 2013
- Enrollment
- 384 (actual)
- Sites
- 38
Conditions
As the registry lists them; a condition with its own page is linked.
coronary heart disease, graft occlusion, vascular